Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario
β Scribed by Annalisa Astolfi; Simona Rolla; Patrizia Nanni; Elena Quaglino; Carla De Giovanni; Manuela Iezzi; Piero Musiani; Guido Forni; Pier-Luigi Lollini; Federica Cavallo; Raffaele A. Calogero
- Publisher
- Springer-Verlag
- Year
- 2005
- Tongue
- English
- Weight
- 728 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The effect of various regimens of treatment with melatonin on the development of mammary tumors in HER2/neu transgenic mice was investigated. Female HERβ2/neu mice starting from the age of 2 months were kept under standard light/dark regimen and as given melatonin with tap water (20 mg/
Transgenic mice carrying the HER-2/neu proto-oncogene under tissue-specific transcriptional control of a mammary tumor virus long terminal repeat (Tg-MMTVneu mice) spontaneously develop mammary carcinomas. HER-2/neu is a tumor antigen that can be recognized by cytotoxic T lymphocytes if tumor cells
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month. Epitalon treatment reduced the cumulative